Abstracts

2022-RA-1131-ESGO

HUMAN PAPILLOMAVIRUS GENOTYPE AND PROGNOSTIC FACTORS OF VAGINAL CANCER

Obstetrics and Gynecology, Chang Gung Memorial Hospital, Linkou Branch and Chang Gung University, Taoyuan City, Taiwan; Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Linkou Branch and Chang Gung University, Taoyuan City, Taiwan; Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Keelung Branch, Keelung City, Taiwan; Department of Pathology, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan City, Taiwan; Clinical Trial Center, Chang Gung Memorial Hospital Linkou Branch, Taoyuan City, Taiwan

Introduction/Background
The natural history of invasive vaginal cancer has been minimally investigated. We aimed to investigate HPV distribution and prognostic factors in vaginal cancer (VC).

Methodology
We retrospectively reviewed medical records of patients with VC who received primary treatment between 1989 and 2020. General polymerase chain reaction (PCR) SPF1/GP6+ followed by revert-blot detection was performed for human papillomavirus (HPV) genotyping. E6 type-specific PCR of the top-5 prevalent types was performed to reconfirm HPV-negative status. P16INK4a immunohistochemistry staining was performed. Univariate and multivariate analyses were performed to identify predictors of clinical outcomes.

Results
A total of 73 vaginal carcinoma patients eligible for analysis. Median follow-up time was 88.6 months (range 0.56–239.5 months). 66 patients (90.4%) were diagnosed as squamous cell carcinoma (SCC) and 7 (9.6%) as non-SCC. HPV DNA sequences were detected in 88.7% of SCC specimens, and 83.3% of non-SCC VC (P = 0.543). The leading types were HPV16 (51.7%), HPV52 (13.3%) and HPV58 (11.7%). HPV-positivity was associated with better 5-year cancer-specific survival (CSS) (70.8% vs 35.7%, P = 0.005). Because there was strong correlation between p16-positivity and HPV-positivity (P <0.001), they were alternatively entered in multivariate analysis. In both models, pelvic lymph node (PLN) metastasis (HR 4.72, 95% confidence interval [CI] 1.50–14.80, P = 0.002) was a significant adverse predictor of CSS, while p16 (HR 0.049, 95% CI 0.01–0.229, P <0.001) or HPV-positivity (HR 0.129, 95%CI 0.036–0.466, P = 0.002) was related to better prognosis. International Federation of Gynecology and Obstetrics stage (III/IV vs I/II) was significant in univariate analysis, but was not significant in either model.

Conclusion
PLN metastasis was a significant adverse predictor, while p16-positivity or HPV-positivity (alternatively) was a significant factor of better prognosis.

Abstract 2022-RA-1131-ESGO Figure 1

Abstract 2022-RA-1131-ESGO Figure 2

2022-VA-1138-ESGO

LAPAROSCOPIC ANTERIOR RESECTION WITH TOTAL VAGINECTOMY

VVN Raju K, Pavan kumar Jorrnda, Zeeba Usofi, B Madhu, K Pradeep, Syed Nusrath.
BIACHRI, hyd, India

Introduction/Background
This is a video demonstration of laparoscopic anterior exenteration with total vaginectomy for vaginal squamous cell cancer in a young female.

Methodology
Techniques of dissection and surgical demonstration of anterior exenteration with total vaginectomy

Results
Video demonstrated in the given format

Conclusion
Laparoscopic anterior exenteration with total vaginectomy is an acceptable surgical procedure with minimal morbidity for the management of locally advanced vaginal cancer.

Abstract 2022-VA-1138-ESGO

2022-VA-1152-ESGO

SIGMOID NEOVAGINA AND DOUBLE V-Y FLAP RECONSTRUCTION AFTER A TOTAL PELVIC INFRALEVATOR EXENTERATION

Felix Boria, Enrique Chacón, Monica Gutierrez, Nabil Manzour, Teresa Castellanos, Daniel Vazquez, Luis Chiva.
Gynecologic oncology department, Clínica Universidad de Navarra, Madrid, Spain; Gynecologic oncology, Clínica Universidad de Navarra, Pamplona, Spain; Gynecologic oncology, Clínica Universidad de Navarra, Madrid, Spain

Introduction/Background
This is a video demonstration of sigmoid neovagina with double V-Y flap reconstruction after a total pelvic infrallevator exenteration

Conclusion
This is a video demonstration of sigmoid neovagina with double V-Y flap reconstruction after a total pelvic infrallevator exenteration

Abstract 2022-VA-1152-ESGO

Int J Gynecol Cancer 2022;32(Suppl 2):A1–A504